Rituximab maintenance improves outcomes of transformed diffuse large B-cell lymphoma: a retrospective study of 519 cases with

Antineoplastic Combined Chemotherapy Protocols / adverse effects Humans Lymphoma, Follicular / drug therapy Lymphoma, Large B-Cell, Diffuse / drug therapy Neoplasm Recurrence, Local Prognosis Retrospective Studies Rituximab / therapeutic use
DLBCL concurrent DLBCL and FL prognosis rituximab maintenance transformation

Journal

Leukemia & lymphoma
ISSN: 1029-2403
Titre abrégé: Leuk Lymphoma
Pays: United States
ID NLM: 9007422

Informations de publication

Date de publication:
09 2021
Historique:
pubmed: 23 3 2021
medline: 25 2 2023
entrez: 22 3 2021
Statut: ppublish

Résumé

Although outcomes of transformed diffuse large B-cell lymphoma (DLBCL) from follicular lymphoma (FL) were improved using rituximab-combined immunochemotherapy, the efficacy of subsequent rituximab maintenance (RM) remains unclear. We retrospectively analyzed the prognoses of 519 patients with

Identifiants

DOI: 10.1080/10428194.2021.1901091 PMID: 33749498
pubmed: 33749498
doi: 10.1080/10428194.2021.1901091
doi:

Substances chimiques

Rituximab 4F4X42SYQ6

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

2141-2150

Auteurs

Hideki Uryu (H)

Department of Hematology Oncology, The Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan.
ORCID: 0000-0002-1891-9838

Yuko Mishima (Y)

Department of Hematology Oncology, The Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan.

Naoko Tsuyama (N)

Division of Pathology, The Cancer Institute, Japanese Foundation for Cancer Research, Tokyo, Japan.

Masahiro Yokoyama (M)

Department of Hematology Oncology, The Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan.

Noriko Nishimura (N)

Department of Hematology Oncology, The Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan.

Takanori Fukuta (T)

Department of Hematology Oncology, The Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan.

Yuko Shirouchi (Y)

Department of Hematology Oncology, The Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan.
ORCID: 0000-0003-0945-2030

Takashi Okabe (T)

Department of Hematology Oncology, The Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan.

Norihito Inoue (N)

Department of Hematology Oncology, The Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan.
Division of Pathology, The Cancer Institute, Japanese Foundation for Cancer Research, Tokyo, Japan.

Kengo Takeuchi (K)

Division of Pathology, The Cancer Institute, Japanese Foundation for Cancer Research, Tokyo, Japan.
Pathology Project for Molecular Targets, The Cancer Institute, Japanese Foundation for Cancer Research, Tokyo, Japan.

Yasuhito Terui (Y)

Department of Hematology Oncology, The Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Thérapeutique › Traitement médicamenteux › Association de médicaments › Protocoles de polychimiothérapie antinéoplasique › Rituximab maintenance improves outcomes of...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Rituximab maintenance improves outcomes of...
questionsmedicales.fr › Maladies du système immunitaire › Syndromes immunoprolifératifs › Syndromes lymphoprolifératifs › Lymphomes › Lymphome malin non hodgkinien › Lymphome folliculaire › Rituximab maintenance improves outcomes of...
questionsmedicales.fr › Maladies du système immunitaire › Syndromes immunoprolifératifs › Syndromes lymphoprolifératifs › Lymphomes › Lymphome malin non hodgkinien › Lymphome B › Lymphome B diffus à grandes cellules › Rituximab maintenance improves outcomes of...
questionsmedicales.fr › États, signes et symptômes pathologiques › Processus pathologiques › Processus néoplasiques › Récidive tumorale locale › Rituximab maintenance improves outcomes of...
questionsmedicales.fr › Diagnostic › Pronostic › Rituximab maintenance improves outcomes of...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Caractéristiques des études épidémiologiques › Études épidémiologiques › Études de cohortes › Études rétrospectives › Rituximab maintenance improves outcomes of...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Globulines › Sérum-globulines › Immunoglobulines › Anticorps › Anticorps monoclonaux › Anticorps monoclonaux d'origine murine › Rituximab › Rituximab maintenance improves outcomes of...